Target intelligence / Profile preview

Protein prenyltransferase alpha subunit repeat containing 1 (PTAR1)

Target
PTAR1
Molecular classification
Enzyme, Prenyltransferase (specifically “geranylgeranyltransferase III” subunit)
01

Overview

PTAR1 is the alpha subunit of a newly characterized protein prenyltransferase, GGTase-III, which partners with the RabGGTB beta subunit to transfer geranylgeranyl groups specifically to substrates such as FBXL2 and Ykt6[2][4]. This modification is vital for anchoring these target proteins to cellular membranes, controlling their localization and turnover. PTAR1-mediated geranylgeranylation of FBXL2 influences membrane protein polyubiquitylation, while modification of Ykt6 is essential for Golgi membrane integration and SNARE complex formation, contributing to vesicular trafficking and maintenance of organellar structure[2]. PTAR1 resides primarily in the mitochondria but is also implicated in broader organelle functions[3]. Although no drugs currently target PTAR1 directly, the enzyme’s activity is linked to disease mechanisms including cancer and membrane homeostasis.

Other names
PTAR1Protein prenyltransferase alpha subunit repeat-containing protein 1Protein prenyltransferase alpha subunit repeat containing 1
02

Mechanism of action

Drugs interacting with prenyltransferases typically act by inhibiting prenyl group transfer, disrupting membrane localization and downstream signaling of target substrates[1][2]. For GGTase inhibitors, the mechanism is blockade of geranylgeranylation.

03

Biological functions

Protein prenyltransferase activity (catalyzes transfer of lipid groups to proteins)Geranylgeranylation of membrane-associated proteinsRegulation of membrane localizationProtein turnoverVesicular transport and Golgi dynamics
04

Disease associations

Cancer (related to FBXL2 pathway and membrane turnover; included in cancer co-expression modules)Other (general cell membrane trafficking, with implications in cellular homeostasis and disease when dysregulated)
05

Safety considerations

Direct PTAR1 inhibition could interfere broadly with cellular trafficking and protein turnover; potential toxicity (off-target effects) is not well-characterized due to lack of direct inhibitors
06

Biomarkers

None currently established for patient selection or efficacy monitoring specific to PTAR1; downstream substrates (FBXL2, Ykt6) could be indirect functional markers

Beyond the preview

Go deeper on Protein prenyltransferase alpha subunit repeat containing 1 (PTAR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein prenyltransferase alpha subunit repeat containing 1 (PTAR1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call